LEP and prostate carcinoma: Long-term exposure to leptin was shown to enhance the growth of all three main prostate cancer cell lines (LNCaP, DU145 and PC-3) [53], where androgen-insensitive prostate cancer cell lines DU145 and PC-3 show a stronger proliferative response to leptin treatment in comparison to androgen-sensitive LNCaP cells [54].